Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.
about
Human ADA2 belongs to a new family of growth factors with adenosine deaminase activityThe Production Processes and Biological Effects of Intravenous ImmunoglobulinProduction of plasma-derived medicinal products: ethical implications for blood donation and donorsFibrin-based biomaterials: modulation of macroscopic properties through rational design at the molecular level.Overview of Albumin and Its Purification MethodsAn efficient targeted drug delivery through apotransferrin loaded nanoparticlesEfficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in ratsProteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritusHuman Bone Marrow Mesenchymal Stem/Stromal Cells Preserve Their Immunomodulatory and Chemotactic Properties When Expanded in a Human Plasma Derived Xeno-Free Medium.Investigation of an albumin-enriched fraction of human serum and its albuminome.Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.A program of Yersinia enterocolitica type III secretion reactions is activated by specific signalsJeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?Genomic and surface proteomic analysis of the canine pathogen Staphylococcus pseudintermedius reveals proteins that mediate adherence to the extracellular matrix.A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid.Culture of human mesenchymal stem cells using a candidate pharmaceutical grade xeno-free cell culture supplement derived from industrial human plasma pools.Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.Plasma-derived medicines: access and usage issuesCryoprecipitate therapy.Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples.Identification of a phage-encoded Ig-binding protein from invasive Neisseria meningitidis.Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.Richard Havel, Howard Eder, and the evolution of lipoprotein analysisLipoprotein-inspired nanoparticles for cancer theranosticsReview of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.Hemodilution is not critical in the pathogenesis of the acute coagulopathy of trauma.The early years of lipoprotein research: from discovery to clinical application.Human mesenchymal stem cells maintain their phenotype, multipotentiality, and genetic stability when cultured using a defined xeno-free human plasma fraction.Comparative Study of Two ELISA Kits for Estimation of Antibodies to Hepatitis B Virus in Human Normal Immunoglobulin and Specific Immunoglobulin Intended for Intravenous or Intramuscular Use.Proteomic and network analysis of human serum albuminome by integrated use of quick crosslinking and two-step precipitation.Implementation of Plasma Fractionation in Biological Medicines ProductionA target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer.Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.HDL structure and function is profoundly affected when stored frozen in the absence of cryoprotectants.Xeno-Free Strategies for Safe Human Mesenchymal Stem/Stromal Cell Expansion: Supplements and Coatings.Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections
P2860
Q24536231-A26944B8-8A37-4978-888C-F93123C8DE19Q26752540-1C802794-F84C-46BE-B04D-5C74318C17BBQ26996982-23E1801E-F177-42CC-B716-7517D9960F43Q27003215-A9901772-77C0-4815-B19B-65A2325D9CEFQ28468555-EFE4DAAC-7B1C-468B-A996-BAA80236D74EQ28476276-3E0F3610-DC93-427D-80FB-3651C43EC6A5Q28484539-6DDB23DA-4381-47A3-9553-CD908574A955Q28742619-E1EB7C1A-A9C5-43DB-8801-5C814411DBEBQ30853758-8DA99AF1-ACFC-4BAE-9663-97E8EFF6831DQ33701508-3CD42590-9825-4E56-BFB5-6ADF93D271ABQ33762502-DCDB6C08-6A8C-40FD-B01D-CCED0A518E8FQ33996710-2A6C2333-B295-439E-A03F-6CE5B07BFD72Q35049058-0B7DE58E-4BD8-4914-9127-044E904D5318Q35139269-062C9BF8-75AA-4C08-8059-7A4946BE3B0CQ35156254-1151FB30-21F5-4006-820C-B4080B0D75C1Q35403742-A7E4B44F-FCF6-4E12-89E1-72DE97C48F30Q36074636-BEF6B3B7-A7EB-459A-AAEA-99F200C76A15Q36159943-CAB27881-5D91-4C90-A77D-DF7E555BFD12Q36232259-6B49EB8F-C40F-42D1-99EC-ABD3AAF305EDQ36931787-6A13649B-7187-4C74-9955-3B166ECBBE72Q37191264-E4BBF39E-323A-4745-AEB0-5486CD2B7527Q37318222-36DA5CD8-2179-4528-986C-91F984A5FF35Q37574603-28845F2D-5600-4A34-BF25-B828176FCF8DQ37873918-A9CCBE9E-F8C7-4E8E-937C-C0C4F2ECBD90Q38042583-80B4AA3F-5099-40D2-A05C-2F1E235E7BCCQ38558714-208D3345-7AC5-4D35-ADAA-5902C68052D7Q38913108-E0578B03-3EEB-4E33-B067-909C3F387672Q40224864-67C7F50D-5E79-4CFF-9B9F-27A57A793DB5Q40233603-4990F96D-A050-4BD5-A813-7E2A96CBE905Q41550303-AB1F8AD5-5E29-4670-AF6E-67C90BD5557BQ41674093-7DB12944-4ACA-4E07-8B27-47EFB4AEAF52Q42007121-2151E4B2-6DA8-4912-940B-D307A88DD8D1Q42119487-2427D2AF-EB07-4777-9320-207D42AA6435Q42368365-C0B17435-855F-46AC-99A9-E34303A7EE48Q43748722-C6521449-7AAB-47A5-8081-758737F7A8EAQ47144623-9568B751-0DD0-4D58-A3DC-18D9630EB78CQ47151826-2072B79B-D964-4E12-B92C-6FA54027144EQ58712827-82E9CDF2-0378-4A3E-94A0-DA30AD06A845
P2860
Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.
description
1946 nî lūn-bûn
@nan
1946年の論文
@ja
1946年学术文章
@wuu
1946年学术文章
@zh
1946年学术文章
@zh-cn
1946年学术文章
@zh-hans
1946年学术文章
@zh-my
1946年学术文章
@zh-sg
1946年學術文章
@yue
1946年學術文章
@zh-hant
name
Preparation and properties of ...... biological tissues and fluids.
@en
Preparation and properties of ...... biological tissues and fluids.
@nl
type
label
Preparation and properties of ...... biological tissues and fluids.
@en
Preparation and properties of ...... biological tissues and fluids.
@nl
prefLabel
Preparation and properties of ...... biological tissues and fluids.
@en
Preparation and properties of ...... biological tissues and fluids.
@nl
P356
P1476
Preparation and properties of ...... biological tissues and fluids
@en
P2093
P304
P356
10.1021/JA01207A034
P407
P577
1946-03-01T00:00:00Z